Noradrenaline release in rodent tissues is inhibited by interleukin-1β but is not affected by urotensin II, MCH, NPW and NPFF

Pharmacological Reports

Volumn 63, Issue 1, 2011, Pages 102-111

  Schulte, Kirsten ^a   Kumar, Manush ^a   Zajac, Jean Marie ^b   Schlicker, Eberhard ^a  

^a UNIVERSITY OF BONN   (Germany)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Interleukin 1 ; Melanin concentrating hormone; Neuropeptide FF; Neuropeptide W; Noradrenaline release; Superfusion experiments; Urotensin II

Indexed keywords

ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; INTERLEUKIN 1BETA; MELANIN CONCENTRATING HORMONE; NALTRINDOLE; NEUROPEPTIDE; NEUROPEPTIDE FF; NEUROPEPTIDE W; NORADRENALIN; PRESYNAPTIC RECEPTOR; SULPROSTONE; TRITIUM; UNCLASSIFIED DRUG; UROTENSIN II;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HEART ATRIUM; HIPPOCAMPUS; HYPOTHALAMUS; INHIBITION KINETICS; ISOTOPE LABELING; KIDNEY CORTEX; MALE; MOUSE; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC NERVE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RAT; TISSUE SPECIFICITY;

EID: 79953166858     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70404-2     Document Type: Article

References (41)

1. Alexander SPH, Mathie A, Peters JA: Guide to receptors and channels (GRAC), 4th edn. Br J Pharmacol, 2009, 158, Suppl 1, S1-S254.
2. Allard M, Labrouche S, Nosjean A, Laguzzi R: Mechanisms underlying the cardiovascular responses to peripheral administration of NPFF in the rat. J Pharmacol Exp Ther, 1995, 274, 577-583.
3. Behm DJ, Herold CL, Camarda V, Aiyar NV, Douglas SA: Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Eur J Pharmacol, 2004, 492, 113-116. (Pubitemid 38721360)
4. Bognar IT, Albrecht SA, Farasaty M, Schmitt E, Seidel G, Fuder H: Effects of human recombinant interleukins on stimulation-evoked noradrenaline overflow from the rat perfused spleen. Naunyn-Schmiedeberg's Arch Pharmacol, 1994, 349, 497-502. (Pubitemid 24135131)
5. Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE et al.: Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem, 2000, 275, 39324-39331. (Pubitemid 32058954)
6. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM et al.: Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998, 95, 15803-15808. (Pubitemid 29018781)
7. Cox SL, Schelb V, Trendelenburg AU, Starke K: Enhancement of noradrenaline release by angiotensin II and bradykinin in mouse atria: evidence for cross-talk between Gq/11 protein- and Gi/o protein-coupled receptors. Br J Pharmacol, 2000, 129, 1095-1102. (Pubitemid 30153965)
8. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood, 1996, 87, 2095-2147.
9. Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol, 2009, 27, 519-550.
10. Disa J, Floyd LE, Edwards RM, Douglas SA, Aiyar NV: Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography. Peptides, 2006, 27, 1532-1537. (Pubitemid 43766989)
11. Douglas SA, Dhanak D, Johns DG : From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci, 2004, 25, 76-85.
12. 2 on noradrenaline release in the mouse brain cortex. Naunyn-Schmiedeberg's Arch Pharmacol, 1995, 351, 46-52.
13. Gao XB, van den Pol AN: Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus. J Physiol, 2001, 533, 237-252.
14. 3 receptor antagonist L-826,266. Naunyn-Schmiedeberg's Arch Pharmacol, 2010, 381, 21-31.
15. Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, Nasir S, Leslie RA: The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur J Neurosci, 2000, 12, 1194-1216. (Pubitemid 30224225)
16. Huang EY, Li JY, Tan PP, Wong CH, Chen JC: The cardiovascular effects of PFRFamide and PFR(Tic)amide, a possible agonist and antagonist of neuropeptide FF (NPFF). Peptides, 2000, 21, 205-210.
17. Hurst S, Collins SM: Interleukin-1 beta modulation of norepinephrine release from rat myenteric nerves. Am J Physiol, 1993, 264, G30-G35. (Pubitemid 23055985)
18. Jhamandas JH, MacTavish D, Harris KH: Neuropeptide FF (NPFF) control of magnocellular neurosecretory cells of the rat hypothalamic paraventricular nucleus (PVN). Peptides, 2006, 27, 973-979.
19. Jhamandas JH, Simonin F, Bourguignon JJ, Harris KH: Neuropeptide FF and neuropeptide VF inhibit GABA-ergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol, 2007, 292, R1872-R1880. (Pubitemid 46708542)
20. Kawauchi H, Kawazoe I, Tsubokawa M, Kishida M, Baker BI: Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature, 1983, 305, 321-323. (Pubitemid 13010926)
21. Langer SZ: Therapeutic use of release-modifying drugs. In: Pharmacology of Neurotransmitter Release, Handbook of Experimental Pharmacology, vol. 184. Eds. Südhof TC, Starke K, Springer, Berlin, Heidelberg, 2008, 561-573.
22. Mollereau C, Roumy M, Zajac JM: Opioid-modulating peptides: mechanisms of action. Curr Top Med Chem, 2005, 5, 341-355. (Pubitemid 40614134)
23. Ono T, Kawaguchi Y, Kudo M, Kushikata T, Hashiba E, Yoshida H, Kudo T: Urotensin II evokes neurotransmitter release from rat cerebrocortical slices. Neurosci Lett, 2008, 440, 275-279.
24. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA: Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA, 1980, 77, 5021-5024. (Pubitemid 11236553)
25. Quan N, Banks WA: Brain-immune communication pathways. Brain Behav Immunity, 2007, 21, 727-735. (Pubitemid 47002217)
26. Rosmaninho-Salgado J, Alvaro AR, Grouzmann E, Duarte EP, Cavadas C: Neuropeptide Y regulates catecholamine release evoked by interleukin-1β in mouse chromaffin cells. Peptides, 2007, 28, 310-314. (Pubitemid 46176276)
27. 2 agonist depends on opioid activity. Biochem Biophys Res Commun, 2005, 336, 197-203.
28. Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry, 1965, 122, 509-522.
29. 2-autoreceptor and presynaptic inhibitory heteroreceptors on noradrenergic neurones. Brain Res Bull, 1998, 47, 129-132.
30. Schlicker E, Kathmann M: Presynaptic neuropeptide receptors. In: Pharmacology of Neurotransmitter Release, Handbook of Experimental Pharmacology, vol. 184. Eds. Südhof TC, Starke K, Springer, Berlin, Heidelberg, 2008, 409-434.
31. Shimomura Y, Harada M, Goto M, Sugo T, Matsumoto Y, Abe M, Watanabe T et al.: Identification of neuropeptide Was the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem, 2002, 277, 35826-35832.
32. Singh G, Davenport AP. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system. Br J Pharmacol, 2006, 148, 1033-1041. (Pubitemid 44223008)
33. 125I]-NPW radioligand binding and immunocytochemistry. Brain Res, 2004, 1017, 222-226.
34. Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G: Activation of brain interleukin-1β in schizophrenia. Mol Psychiatry, 2009, 14, 1069-1071.
35. Song C, Horrobin DF, Leonard BE: The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1β in rats. Pharmacopsychiatry, 2006, 39, 88-99. (Pubitemid 43901620)
36. Starke K: Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol, 1977, 77, 1-124.
37. Stegbauer J, Vonend O, Oberhauser V, Sellin L, Rump LC: Angiotensin II receptor modulation of renal vascular resistance and neurotransmission in young and adult spontaneously hypertensive rats. Kidney Blood Press Res, 2005, 28, 20-26. (Pubitemid 40069633)
38. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues. Br J Pharmacol, 2000, 130, 321-330.
39. Tsumori C, Shibasaki T, Hotta M, Takeuchi K, Yamauchi N, Imaki T, Wakabayashi I, Demura H: Interleukin-1beta administered intracerebroventricularly stimulates the release of noradrenaline in the hypothalamic paraventricular nucleus via prostaglandin in the rat. Endocr J, 1998, 45, 127-130. (Pubitemid 28152495)
40. Vaughan JM, Fischer WH, Hoeger C, Rivier J, Vale W: Characterization of melanin-concentrating hormone from rat hypothalamus. Endocrinology, 1989, 125, 1660-1665. (Pubitemid 19224024)
41. Yang HY, Fratta W, Majane EA, Costa E: Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA, 1985, 82, 7757-7761. (Pubitemid 16204428)